Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Biochemistry

Background:

• The mitogen-activated protein kinase (MAPK) pathway is crucial for cell regulation and frequently dysregulated in cancer.
• B-RAF kinase, particularly the V600E mutation common in melanoma, is a significant therapeutic target.
• Pyrimido[4,5-d]pyrimidines represent an underexplored scaffold for kinase inhibitor development.

Purpose of the Study:

• To design, synthesize, and evaluate novel pyrimido[4,5-d]pyrimidine derivatives as B-RAF inhibitors.
• To investigate the binding mode and selectivity of these compounds against B-RAF V600E.
• To assess the antiproliferative activity of the synthesized compounds in cancer cell lines.

Main Methods:

• Rational drug design incorporating pharmacophoric features of known B-RAF inhibitors.
• Synthesis of pyrimido[4,5-d]pyrimidine derivatives.
• Kinase profiling using differential scanning fluorimetry (DSF) and isothermal titration calorimetry (ITC).
• Molecular docking studies to predict binding modes.
• Antiproliferative assays in T24 and WM266-4 cancer cells.

Main Results:

• Compound 15 exhibited selective binding to B-RAF V600E (Kd = 98 nM) with a type-II binding mode.
• Compound 15 displayed modest antiproliferative effects, potentially due to poor cell permeability.
• Compounds 16, 17, and 22 showed significant cellular activity, suggesting off-target effects or alternative mechanisms.
• DSF Tm shifts confirmed the potential of pyrimido[4,5-d]pyrimidines as ATP mimetic scaffolds.

Conclusions:

• Pyrimido[4,5-d]pyrimidines are promising scaffolds for developing kinase inhibitors.
• Compound 15 demonstrates selective biochemical inhibition of B-RAF V600E.
• Further optimization is needed to improve cellular activity and overcome potential resistance mechanisms.